M28 Capital Management LP reported 9 positions worth $47.16M for the quarter ended Jun 30, 2026, down 12.3% on the prior quarter. It opened 0 new positions, added to 0, trimmed 0 and exited 0. Its largest holding is Wave Life Sciences, Inc. at 56.5% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
No positions were reduced this quarter.
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | WVE Wave Life Sciences, Inc. | Healthcare | 4.59M | $26.66M | 56.53% | 0 | 0.0% | Unchanged | 2.25% |
| 2 | IVVD Invivyd, Inc. | Healthcare | 9.25M | $8.07M | 17.11% | 0 | 0.0% | Unchanged | 2.89% |
| 3 | TGTX Tg Therapeutics, Inc. | Healthcare | 88.4K | $4.85M | 10.29% | 0 | 0.0% | Unchanged | 0.06% |
| 4 | ARWR Arrowhead Pharmaceuticals, Inc. | Healthcare | 36.9K | $3.00M | 6.37% | 0 | 0.0% | Unchanged | 0.03% |
| 5 | GUTS Fractyl Health, Inc. | Healthcare | 154.7K | $1.47M | 3.13% | 0 | 0.0% | Unchanged | 1.17% |
| 6 | PRQR ProQR Therapeutics N.V. | Healthcare | 599.8K | $1.12M | 2.37% | 0 | 0.0% | Unchanged | 0.57% |
| 7 | SLN Silence Therapeutics plc | Healthcare | 101.2K | $1.11M | 2.36% | 0 | 0.0% | Unchanged | 0.21% |
| 8 | RCKT Rocket Pharmaceuticals, Inc. | Healthcare | 210.9K | $721.18K | 1.53% | 0 | 0.0% | Unchanged | 0.19% |
| 9 | CRIS Curis Inc | Healthcare | 14.2K | $148.74K | 0.315% | 0 | 0.0% | Unchanged | 0.67% |
Tip. Select a row to see that position’s full history at M28 Capital Management.
As of its Q2 2026 13F filing, M28 Capital Management LP’s five largest positions were Wave Life Sciences, Inc. (WVE) at 56.5%, Invivyd, Inc. (IVVD) at 17.1%, Tg Therapeutics, Inc. (TGTX) at 10.3%, Arrowhead Pharmaceuticals, Inc. (ARWR) at 6.4%, Fractyl Health, Inc. (GUTS) at 3.1% of the reported portfolio.
M28 Capital Management LP reported a 13F portfolio worth $47.16M across 9 positions for Q2 2026. That is down 12.3% from the previous quarter.
From the Form 13F-HR reports M28 Capital Management LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.